Cite
HARVARD Citation
Evans, M. et al. (2016). Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective. Diabetes therapy. 7 (4), pp. 809-823. [Online].